Menu
Search
|

Menu

Close
X

vTv Therapeutics Inc VTVT.OQ (NASDAQ Stock Exchange Global Market)

6.96 USD
+0.33 (+4.98%)
As of Feb 20
chart
Previous Close 6.63
Open 6.66
Volume 36,998
3m Avg Volume 48,974
Today’s High 7.20
Today’s Low 6.66
52 Week High 8.37
52 Week Low 3.63
Shares Outstanding (mil) 32.81
Market Capitalization (mil) 204.09
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
1
FY15
1
EPS (USD)
FY17
-0.844
FY16
-1.713
FY15
-1.456
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
1,715.07
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
-134.79
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Jeffrey Kindler
Executive Chairman of the Board, Since 2015
Salary: --
Bonus: --
Stephen Holcombe
President, Chief Executive Officer, Since 2015
Salary: --
Bonus: --
Rudy Howard
Chief Financial Officer, Executive Vice President, Since 2015
Salary: --
Bonus: --
Larry Altstiel
Chief Medical Officer, Since 2016
Salary: --
Bonus: --
Steven Cohen
Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4170 Mendenhall Oaks Pkwy
HIGH POINT   NC   27265-8345

Phone: +1336.8410300

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

SPONSORED STORIES